Tag: Lynparza
Merck and co inc: Failure of a phase III trial on Keytruda + Lynparza
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
AstraZeneca: Towards a new indication for Lynparza
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: towards a new indication for Lynparza
(CercleFinance.com) – The Committee for Medicinal Products for Human Use (CHMP) announced on Friday that it had adopted a favorable opinion with a view to marketing AstraZeneca’s Lynparza in a…
AstraZeneca: priority review for Lynparza in the USA
(CercleFinance.com) – AstraZeneca announced on Thursday that its cancer tablet Lynparza will receive priority review in the United States for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Lynparza, developed…
AstraZeneca: a new positive opinion from the CHMP for Lynparza
(CercleFinance.com) – The European Medicines Agency announced on Friday that its Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion on a new indication for Lynparza,…
AstraZeneca: Positive clinical trials on Lynparza
(CercleFinance.com) – AstraZeneca gained more than 2.5% on the British stock market on Tuesday after the announcement of the success of a clinical trial in the treatment of prostate cancer.…